SCHEMBL1131839

SCHEMBL1131839

COC(=O)C=Cc1cc(C2CCCCC2)n(-c2ccc(OCc3ccccc3)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 1/20 0.42
MDM2 Q00987 2/20 0.41
CRACR2A Q9BSW2 1/20 0.41
BCL2 P10415 1/20 0.41
MCL1 Q07820 1/20 0.41
GSK3B P49841 1/20 0.40
BACE1 P56817 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MMP1 P03956 1/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MAP3K7 O43318 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131754 1.00 KDM4E (0.42) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1131667 0.91 KDM4E (0.44) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1131668 0.91 KDM4E (0.44) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1131251 0.84 CA12 (0.43) KDM4EKMT2ACRACR2AALDH1A1HPGD
SCHEMBL1131257 0.84 CA12 (0.43) KDM4EKMT2ACRACR2AALDH1A1HPGD
SCHEMBL1131017 0.83 MDM2 (0.43) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1131756 0.83 KDM4E (0.43) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1132002 0.83 KDM4E (0.43) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1132075 0.81 MDM2 (0.60) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A
SCHEMBL1131566 0.80 SMN1; SMN2 (0.42) KDM4ESMN1; SMN2KMT2AMDM2CRACR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP claimed
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP disclosed